Literature DB >> 11159730

Transcriptional and translational regulation of calpain in the rat heart after myocardial infarction--effects of AT(1) and AT(2) receptor antagonists and ACE inhibitor.

S Sandmann1, M Yu, T Unger.   

Abstract

1. Recent studies demonstrated that the cardiac calpain system is activated during ischaemic events and is involved in cardiomyocyte injury. The aim of this study was to investigate the contribution of AT(1) and AT(2) receptors in the regulation of calpain-mediated myocardial damage following myocardial infarction (MI). 2. Infarcted animals were treated either with placebo, the ACE inhibitor ramipril (1 mg kg(-1) d(-1)), the AT(1) receptor antagonist valsartan (10 mg kg(-1) d(-1)) or the AT(2) receptor antagonist PD 123319 (30 mg kg(-1) d(-1)). Treatment was started 7 days prior to surgery. On day 1, 3, 7 and 14 after MI, gene expression and protein levels of calpain I, II and calpastatin were determined in left ventricular free wall (LVFW) and interventricular septum (IS). At day 3 and 14 post MI, morphological investigations were performed. 3. Calpain I mRNA expression and protein levels were increased in IS 14 days post MI, whereas mRNA expression and protein levels of calpain II were maximally increased in LVFW 3 days post MI. Ramipril and valsartan decreased mRNA and protein up-regulation of calpain I and II, and reduced infarct size and interstitial fibrosis. PD 123319 did not affect calpain I or II up-regulation in the infarcted myocardium, but decreased interstitial fibrosis. Calpastatin expression and translation were not affected by AT receptor antagonists or ACE inhibitor. 4. Our data demonstrate a distinct, temporary-spatial up-regulation of calpain I and II following MI confer with the hypothesis of calpain I being involved in cardiac remodelling in the late and calpain II contributing to cardiac tissue damage in the early phase of MI. The up-regulation of calpain I and II is partly mediated via the AT(1) receptor and can be reduced by ACE inhibitors and AT(1) receptor antagonists.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11159730      PMCID: PMC1572603          DOI: 10.1038/sj.bjp.0703860

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  55 in total

1.  Immunoblot analysis of calpastatin degradation: evidence for cleavage by calpain in postmortem muscle.

Authors:  M E Doumit; M Koohmaraie
Journal:  J Anim Sci       Date:  1999-06       Impact factor: 3.159

2.  [Duchenne muscular dystrophy].

Authors:  S Ishiura; H Sugita
Journal:  No To Shinkei       Date:  1991-05

3.  Involvement of the renin-angiotensin system in ischemic damage and reperfusion arrhythmias in the isolated perfused rat heart.

Authors:  G Fleetwood; S Boutinet; M Meier; J M Wood
Journal:  J Cardiovasc Pharmacol       Date:  1991-03       Impact factor: 3.105

Review 4.  Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications.

Authors:  M A Pfeffer; E Braunwald
Journal:  Circulation       Date:  1990-04       Impact factor: 29.690

Review 5.  Cytoplasmic [Ca2+] in mammalian ventricle: dynamic control by cellular processes.

Authors:  W G Wier
Journal:  Annu Rev Physiol       Date:  1990       Impact factor: 19.318

Review 6.  Na+/H+ exchange and Ca2+ influx.

Authors:  W Siffert; J W Akkerman
Journal:  FEBS Lett       Date:  1989-12-18       Impact factor: 4.124

7.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators.

Authors:  M A Pfeffer; E Braunwald; L A Moyé; L Basta; E J Brown; T E Cuddy; B R Davis; E M Geltman; S Goldman; G C Flaker
Journal:  N Engl J Med       Date:  1992-09-03       Impact factor: 91.245

8.  Tissue-specific activation of cardiac angiotensin converting enzyme in experimental heart failure.

Authors:  A T Hirsch; C E Talsness; H Schunkert; M Paul; V J Dzau
Journal:  Circ Res       Date:  1991-08       Impact factor: 17.367

9.  Selective activation of cardiac angiotensinogen gene expression in post-infarction ventricular remodeling in the rat.

Authors:  K Lindpaintner; W Lu; N Neidermajer; B Schieffer; H Just; D Ganten; H Drexler
Journal:  J Mol Cell Cardiol       Date:  1993-02       Impact factor: 5.000

10.  Specific alterations in the distribution of extracellular matrix components within rat myocardium during the development of pressure overload.

Authors:  F Contard; V Koteliansky; F Marotte; I Dubus; L Rappaport; J L Samuel
Journal:  Lab Invest       Date:  1991-01       Impact factor: 5.662

View more
  15 in total

Review 1.  Tear me down: role of calpain in the development of cardiac ventricular hypertrophy.

Authors:  Cam Patterson; Andrea L Portbury; Jonathan C Schisler; Monte S Willis
Journal:  Circ Res       Date:  2011-08-05       Impact factor: 17.367

2.  Molecular Determinants of Calpain-dependent Cleavage of Junctophilin-2 Protein in Cardiomyocytes.

Authors:  Ang Guo; Duane Hall; Caimei Zhang; Tianqing Peng; Jordan D Miller; William Kutschke; Chad E Grueter; Frances L Johnson; Richard Z Lin; Long-Sheng Song
Journal:  J Biol Chem       Date:  2015-06-10       Impact factor: 5.157

3.  Receptor-independent cardiac protein kinase Calpha activation by calpain-mediated truncation of regulatory domains.

Authors:  Min-Young Kang; Yan Zhang; Scot J Matkovich; Abhinav Diwan; Athar H Chishti; Gerald W Dorn
Journal:  Circ Res       Date:  2010-08-05       Impact factor: 17.367

4.  Activity profile of calpains I and II in chronically infarcted rat myocardium--influence of the calpain inhibitor CAL 9961.

Authors:  Steffen Sandmann; Freerk Prenzel; Lee Shaw; Roland Schauer; Thomas Unger
Journal:  Br J Pharmacol       Date:  2002-04       Impact factor: 8.739

5.  Calpain 9 as a therapeutic target in TGFβ-induced mesenchymal transition and fibrosis.

Authors:  David H Kim; James D Beckett; Varun Nagpal; Manuel A Seman-Senderos; Russell A Gould; Tyler J Creamer; Elena Gallo MacFarlane; Yichun Chen; Djahida Bedja; Jonathan T Butcher; Wayne Mitzner; Rosanne Rouf; Shoji Hata; Daniel S Warren; Harry C Dietz
Journal:  Sci Transl Med       Date:  2019-07-17       Impact factor: 17.956

Review 6.  Calpains as Potential Therapeutic Targets for Myocardial Hypertrophy.

Authors:  David Aluja; Sara Delgado-Tomás; Marisol Ruiz-Meana; José A Barrabés; Javier Inserte
Journal:  Int J Mol Sci       Date:  2022-04-07       Impact factor: 6.208

7.  An association between the calpastatin (CAST) gene and keratoconus.

Authors:  Xiaohui Li; Yelena Bykhovskaya; Yongming G Tang; Yoana Picornell; Talin Haritunians; Anthony J Aldave; Loretta Szczotka-Flynn; Sudha K Iyengar; Jerome I Rotter; Kent D Taylor; Yaron S Rabinowitz
Journal:  Cornea       Date:  2013-05       Impact factor: 2.651

8.  Modulation by Syk of Bcl-2, calcium and the calpain-calpastatin proteolytic system in human breast cancer cells.

Authors:  Bei Fei; Shuai Yu; Robert L Geahlen
Journal:  Biochim Biophys Acta       Date:  2013-05-16

9.  Calpain-dependent cleavage of N-cadherin is involved in the progression of post-myocardial infarction remodeling.

Authors:  Yoko Kudo-Sakamoto; Hiroshi Akazawa; Kaoru Ito; Jiro Takano; Masamichi Yano; Chizuru Yabumoto; Atsuhiko T Naito; Toru Oka; Jong-Kook Lee; Yasushi Sakata; Jun-ichi Suzuki; Takaomi C Saido; Issei Komuro
Journal:  J Biol Chem       Date:  2014-06-02       Impact factor: 5.157

10.  Over-expression of calpastatin attenuates myocardial injury following myocardial infarction by inhibiting endoplasmic reticulum stress.

Authors:  Shuai Li; Jian Ma; Jing-Bo Li; James C Lacefield; Douglas L Jones; Tian-Qing Peng; Meng Wei
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.